Residency · Residency · Child Adolescent Psychiatry
Pharmacokinetic and Pharmacodynamic Principles in Pediatric Psychopharmacology
Introduction
Prescribing psychotropic medications to children and adolescents requires a thorough understanding of how developmental physiology influences drug behavior. Pharmacokinetics, which describes what the body does to the drug, and pharmacodynamics, which describes what the drug does to the body, differ significantly between pediatric and adult populations. These differences have direct implications for dosing, efficacy, adverse effect profiles, and monitoring strategies.
Pharmacokinetic Principles
Absorption
Oral drug absorption is influenced by gastric pH, gastric emptying time, and intestinal motility, all of which change across development. Neonates have higher gastric pH, meaning their stomachs are less acidic, which can increase absorption of acid-labile drugs. Gastric emptying is slower in neonates and infants, reaching adult rates by approximately six to eight months of age. First-pass metabolism in the liver affects bioavailability and varies with hepatic maturity. Intramuscular absorption is variable in young children due to differences in muscle mass and blood flow compared to adults.
Distribution
Children have a higher proportion of total body water and lower body fat compared to adults. This increases the volume of distribution for hydrophilic drugs and decreases it for lipophilic drugs. Plasma protein binding is reduced in neonates and infants due to lower levels of albumin and alpha-1-acid glycoprotein, resulting in higher free drug fractions that can increase both pharmacological activity and toxicity risk. The blood-brain barrier is more permeable in young children, which potentially increases CNS drug exposure.
Metabolism
Hepatic drug metabolism occurs primarily through Phase I reactions, mediated by cytochrome P450 enzymes, and Phase II conjugation reactions. | CYP Enzyme | Maturation Timeline | Clinical Relevance |
| CYP3A7 → CYP3A4 | Transitions during first year of life | Major metabolizer of many psychotropics | |
|---|---|---|---|
| CYP2D6 | Adult activity by ~age 5 | Metabolizes atomoxetine, risperidone, aripiprazole, some SSRIs | |
| CYP1A2 | Mature by ages 1-2 | Metabolizes clozapine, olanzapine | |
| CYP2C19 | Developmental changes through childhood | Relevant to SSRI metabolism (citalopram, escitalopram) |
CYP enzyme activity varies dramatically with age. CYP3A7 predominates in neonates and transitions to CYP3A4 during the first year of life. CYP2D6 reaches adult activity levels by approximately age five. CYP1A2 matures by ages one to two, and CYP2C19 shows developmental changes relevant to SSRI metabolism. A critically important clinical point is that children between ages two and twelve often have higher weight-adjusted hepatic metabolism than adults, meaning they may require relatively higher mg/kg doses to achieve therapeutic drug levels. Phase II reactions, including glucuronidation and sulfation, mature at variable rates.
Elimination
Glomerular filtration rate is low at birth and reaches adult values by age one to two years. Tubular secretion matures more slowly than GFR. Renal clearance is a key determinant for drugs that are primarily renally excreted, such as lithium and gabapentin. Children may have shorter elimination half-lives for many psychotropic medications, potentially requiring more frequent dosing to maintain therapeutic levels.
Pharmacodynamic Considerations
Receptor Development
Neurotransmitter receptor density, distribution, and sensitivity change throughout development. Serotonin receptors are overexpressed in early childhood and undergo pruning during adolescence. Dopamine receptor maturation in the prefrontal cortex continues into the mid-twenties. GABAergic system development influences the response to benzodiazepines and other sedative medications. Glutamate receptor maturation affects vulnerability to excitotoxicity.
Developmental Sensitivity
The developing brain may show paradoxical responses to certain medications, such as behavioral activation with SSRIs or disinhibition with benzodiazepines. The risk of suicidality with antidepressants is higher in pediatric populations, a finding that led to the FDA's black box warning. Metabolic side effects of atypical antipsychotics, including weight gain and dyslipidemia, may be more pronounced in youth than in adults. The long-term effects of psychotropic medications on brain development remain incompletely understood. Placebo response rates are generally higher in pediatric psychopharmacology trials than in adult studies, which complicates the interpretation of clinical trial data.
Pharmacogenomics
Genetic polymorphisms in CYP2D6, CYP2C19, and CYP3A4 influence drug metabolism in clinically meaningful ways. CYP2D6 poor metabolizers may experience increased side effects with atomoxetine and certain SSRIs. CYP2C19 ultra-rapid metabolizers may have reduced efficacy with citalopram and escitalopram. HLA-B*1502 testing is recommended before prescribing carbamazepine in patients of Southeast Asian descent due to the risk of Stevens-Johnson syndrome. Pharmacogenomic testing is increasingly available, but the evidence for its routine clinical use in children is still evolving.
Drug-Drug Interactions
| Perpetrator Drug | CYP Effect | Affected Drugs | Clinical Consequence |
|---|---|---|---|
| Fluoxetine | Potent CYP2D6 inhibitor | Atomoxetine, risperidone, aripiprazole | Increased levels/toxicity of affected drugs |
| Carbamazepine | Potent CYP3A4 inducer | Many co-administered medications | Reduced levels/efficacy of affected drugs |
| Valproate | Inhibits glucuronidation | Lamotrigine | Increased lamotrigine levels; Stevens-Johnson syndrome risk |
Children on multiple medications are at risk for pharmacokinetic interactions via CYP inhibition or induction. Fluoxetine is a potent CYP2D6 inhibitor and can affect the metabolism of atomoxetine, risperidone, and aripiprazole. Carbamazepine is a potent CYP3A4 inducer that reduces the levels of many co-administered medications. Valproate inhibits glucuronidation and can increase lamotrigine levels, raising the risk of Stevens-Johnson syndrome. A review of the full medication list, including over-the-counter supplements and herbal products, is essential before prescribing.
Clinical Dosing Strategies
Weight-based dosing in mg/kg is standard for many pediatric medications. The guiding principle is to start with low doses and titrate slowly. However, clinicians must also recognize that children may metabolize drugs faster than adults, sometimes requiring higher mg/kg doses to achieve adequate therapeutic levels. Clinical response and side effects should be monitored closely during titration. Therapeutic drug monitoring is available and clinically useful for lithium, valproate, and carbamazepine.
Monitoring and Safety
Baseline parameters should be established before starting any psychotropic medication, including height, weight, BMI, vital signs, and relevant laboratory values. Metabolic parameters such as fasting glucose and lipid panel should be monitored for patients on atypical antipsychotics according to ADA/APA guidelines. ECG monitoring is indicated for medications with cardiac conduction effects, including tricyclic antidepressants, ziprasidone, and high-dose stimulants. Liver function tests should be followed for valproate and carbamazepine. Renal function and serum levels require monitoring for lithium. Ongoing assessment for extrapyramidal symptoms and tardive dyskinesia is necessary for any patient on antipsychotic medication.
Clinical Pearls
Children are not small adults; developmental pharmacokinetics and pharmacodynamics necessitate individualized dosing and monitoring strategies. Higher weight-adjusted metabolic rates in school-age children often mean that mg/kg dosing may exceed adult doses on a per-kilogram basis, which can seem counterintuitive but reflects the reality of faster hepatic metabolism. Pharmacogenomic testing can be a useful adjunct but does not replace careful clinical titration and monitoring. Clinicians must always weigh the risk of medication side effects against the risk of untreated psychiatric illness in the developing child, because both carry consequences for brain development and long-term outcomes.
References
- Findling, R. L., & Stepanova, E. (2018). Clinical Manual of Child and Adolescent Psychopharmacology (3rd ed.). Washington, DC: American Psychiatric Publishing.
- Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., et al. (2003). Developmental pharmacology: drug disposition, action, and therapy in infants and children. New England Journal of Medicine, 349(12), 1157-1167.
- Strawn, J. R., Poweleit, E. A., Ramsey, L. B. (2023). CYP2C19-guided antidepressant dosing in pediatric patients. Pharmacotherapy, 43(1), 20-30.
- Safer, D. J. (2011). Age-grouped differences in adverse drug events from psychotropic medication. Journal of Child and Adolescent Psychopharmacology, 21(4), 299-309.